News
11-09-2010, 06:30 AM
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.
More... (http://www.news-medical.net/news/20101109/Provectus-holds-second-meeting-with-Australian-TGA-to-review-approval-of-PV-10-for-metastatic-melanoma.aspx)
More... (http://www.news-medical.net/news/20101109/Provectus-holds-second-meeting-with-Australian-TGA-to-review-approval-of-PV-10-for-metastatic-melanoma.aspx)